Nobuhiko Uoshima

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 300 citations

Medicine, Hematology, Oncology +4

Human Herpesvirus 6 (HHV-6) Reactivation and HHV-6 Encephalitis After Allogeneic Hematopoietic Cell Transplantation: A Multicenter, Prospective Study

Masao Ogata, Takako Satou, Jun‐ichi Kadota et al. · Clinical Infectious Diseases · 2013 · 195 citations · Full text

Life Sciences, Hematology, Infectious Diseases +11

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia

Masahiro Sakaguchi, Hiroki Yamaguchi, Yuho Najima et al. · Blood Advances · 2018 · 129 citations · Full text

Medicine, Hematology, Molecular Genetics +14

Prognostic impact of <i>CEBPA</i> bZIP domain mutation in acute myeloid leukemia

Satoshi Wakita, Masahiro Sakaguchi, Iekuni Oh et al. · Blood Advances · 2021 · 118 citations · Full text

Medicine, Hematology, Molecular Biology +11